A New Simplified System for the Evaluation of BNCT Pharmaceuticals

Conference · Sun Sep 13 04:00:00 EDT 1998

OSTI ID:1767

Byrne, T E ^[1]; Kabalka, G W; Martin, R C; Miller, L F

---

1. ORNL

A system for testing potential BNCT pharmaceuticals in cell cultures has been developed with the cooperation of Oak Ridge National Laboratory (ORNL), the University of Tennessee Chemistry Department and the University of Tennessee Nuclear Engineering Department. A BNCT test model has been established with the use of the human lung cancer cell line A 549. These cells were maintained in standard laboratory facilities and subjected to boronated chemicals. Following toxicity studies the human luug cancer cells were exposed to {sup 252}Cf neutron sources provided by the Radiochemical Engineering Development Center (REDC) at ORNL The isotope {sup 252}Cf performs effectively for BNCT applications. The neutron spectrum is similar to that of a reactor fission source with an average energy of 2.1 MeV. A 50 mg source of {sup 252}Cf moderated by water provides a source on the order of 1 x 10{sup 9} thermal neutrons/cm{sup 2}/sec at a distance of 3 cm. The half-life of {sup 252}Cf is 2.65 years, and thus may provide a simple and reliable source of neutrons for BNCT in locations without suitable nuclear reactors. The REDC of ORNL stores and processes the U.S. stockpile of {sup 252}Cf.

• Research Organization: Oak Ridge National Lab., TN (US)
• Sponsoring Organization: USDOE Office of Energy Research (ER) (US)
• DOE Contract Number: AC05-96OR22464
• OSTI ID: 1767
• Report Number(s): ORNL/CP-100097; DP 04 50 50 4; DP 04 50 50 4
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BORON
BORON NEUTRON CAPTURE THERAPY
CALIFORNIUM 252
CELL CULTURES
NEOPLASMS
NEUTRON CAPTURE THERAPY
PERFORMANCE TESTING
RADIOPHARMACEUTICALS